tetano
Editor, Senior Moderator
Cancer Med
. 2020 Sep 17.
doi: 10.1002/cam4.3457. Online ahead of print.
Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients
Douglas Tremblay[SUP] 1 [/SUP], Carina Seah[SUP] 2 [/SUP], Thomas Schneider[SUP] 3 [/SUP], Sheena Bhalla[SUP] 1 [/SUP], Jonathan Feld[SUP] 1 [/SUP], Leonard Naymagon[SUP] 1 [/SUP], Bo Wang[SUP] 1 [/SUP], Vaibhav Patel[SUP] 1 [/SUP], Tomi Jun[SUP] 1 [/SUP], Thomas Jandl[SUP] 1 [/SUP], Farah Rahman[SUP] 4 [/SUP], Sean T H Liu[SUP] 4 [/SUP], Judith A Aberg[SUP] 4 [/SUP], Nicole Bouvier[SUP] 4 [/SUP], Mount Sinai Health System Convalescent Plasma Team
Affiliations
Abstract
Background: Patients with malignancy are particularly vulnerable to infection with Severe Acute Respiratory Disease-Coronavirus-2 (SARS-CoV-2) given their immunodeficiency secondary to their underlying disease and cancer-directed therapy. We report a case series of patients with cancer who received convalescent plasma, an investigational therapy for severe Coronavirus Disease 2019 (COVID-19).
Methods: Patients with cancer were identified who received convalescent plasma. Enrolled patients had confirmed COVID-19 with severe or life-threatening disease and were transfused with convalescent plasma from donors with a SARS-CoV-2 anti-spike antibody titer of ≥ 1:320 dilution. Oxygen requirements and clinical outcomes of interests were captured as well as laboratory parameters at baseline and 3 days after treatment.
Results: We identified 24 patients with cancer, 14 of whom had a hematological malignancy, who were treated with convalescent plasma. Fifteen patients (62.5%) were on cancer-directed treatment at the time of COVID-19 infection. After a median of hospital duration of 9 days, 13 patients (54.2%) had been discharged home, 1 patient (4.2%) was still hospitalized, and 10 patients had died (41.7%). Non-intubated patients, particularly those on nasal cannula alone, had favorable outcomes. Three mild febrile non-hemolytic transfusion reactions were observed. C-reactive protein significantly decreased after 3 days of treatment, while other laboratory parameters including ferritin and D-dimer remained unchanged.
Conclusions: Convalescent plasma may be a promising therapy in cancer patients with COVID-19.
Keywords: COVID-19; SARS-CoV-2; cancer; convalescent plasma; malignancy.
. 2020 Sep 17.
doi: 10.1002/cam4.3457. Online ahead of print.
Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients
Douglas Tremblay[SUP] 1 [/SUP], Carina Seah[SUP] 2 [/SUP], Thomas Schneider[SUP] 3 [/SUP], Sheena Bhalla[SUP] 1 [/SUP], Jonathan Feld[SUP] 1 [/SUP], Leonard Naymagon[SUP] 1 [/SUP], Bo Wang[SUP] 1 [/SUP], Vaibhav Patel[SUP] 1 [/SUP], Tomi Jun[SUP] 1 [/SUP], Thomas Jandl[SUP] 1 [/SUP], Farah Rahman[SUP] 4 [/SUP], Sean T H Liu[SUP] 4 [/SUP], Judith A Aberg[SUP] 4 [/SUP], Nicole Bouvier[SUP] 4 [/SUP], Mount Sinai Health System Convalescent Plasma Team
Affiliations
- PMID: 32945149
- DOI: 10.1002/cam4.3457
Abstract
Background: Patients with malignancy are particularly vulnerable to infection with Severe Acute Respiratory Disease-Coronavirus-2 (SARS-CoV-2) given their immunodeficiency secondary to their underlying disease and cancer-directed therapy. We report a case series of patients with cancer who received convalescent plasma, an investigational therapy for severe Coronavirus Disease 2019 (COVID-19).
Methods: Patients with cancer were identified who received convalescent plasma. Enrolled patients had confirmed COVID-19 with severe or life-threatening disease and were transfused with convalescent plasma from donors with a SARS-CoV-2 anti-spike antibody titer of ≥ 1:320 dilution. Oxygen requirements and clinical outcomes of interests were captured as well as laboratory parameters at baseline and 3 days after treatment.
Results: We identified 24 patients with cancer, 14 of whom had a hematological malignancy, who were treated with convalescent plasma. Fifteen patients (62.5%) were on cancer-directed treatment at the time of COVID-19 infection. After a median of hospital duration of 9 days, 13 patients (54.2%) had been discharged home, 1 patient (4.2%) was still hospitalized, and 10 patients had died (41.7%). Non-intubated patients, particularly those on nasal cannula alone, had favorable outcomes. Three mild febrile non-hemolytic transfusion reactions were observed. C-reactive protein significantly decreased after 3 days of treatment, while other laboratory parameters including ferritin and D-dimer remained unchanged.
Conclusions: Convalescent plasma may be a promising therapy in cancer patients with COVID-19.
Keywords: COVID-19; SARS-CoV-2; cancer; convalescent plasma; malignancy.